Jordan S. Orange, MD, PHD
Overview
Jordan Scott Orange, MD, PhD, chair of pediatrics at Columbia University College of Physicians and Surgeons and physician-in-chief of NewYork-Presbyterian/Morgan Stanley Children’s Hospital, comes to Columbia from Baylor College of Medicine, where he was vice chair for research in Pediatrics, director of the Pediatrician-Scientist Training and Development Program, and chief of immunology, allergy, and rheumatology. At Texas Children's Hospital Dr. Orange held the Louis and Marybeth Pawleek Endowed Chair, and was director of the Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiency and of the Center for Human Immunobiology.
An international leader in pediatric primary immunodeficiency and the immunobiology of human natural killer cells, in his research Dr. Orange combines novel disease discovery with basic cell research to translate underlying biological mechanisms of disease into clinical applications. His research has been continuously funded by the National Institutes of Health and he has published over 250 papers. Dr. Orange is a member of the American Society for Clinical Investigation and the American Pediatric Society and was a recipient of the E. Mead Johnson Award for research accomplishment in pediatrics from the Society for Pediatric Research.
Dr. Orange received his AB, PhD, and MD degrees from Brown University, and went on to residency training at Children's Hospital of Philadelphia, clinical fellowship at Boston Children's Hospital, and a post-doctoral research fellowship at Harvard. He served for nearly 10 years on the faculty of the University of Pennsylvania School of Medicine before moving to Houston in 2012.
Areas of Expertise / Conditions Treated
- Immunodeficiencies Treatments
- Immunodeficiency Disorder
- Pediatric Immunology
- Severe Combined Immunodeficiency (SCID)
Academic Appointments
- Reuben S. Carpentier Professor of Pediatrics
Administrative Titles
- Chair, Department of Pediatrics
Hospital Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
- NewYork-Presbyterian Morgan Stanley Children's Hospital
Gender
- Male
Schedule an Appointment
Phone Appointments
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Location(s)
Credentials & Experience
Education & Training
- MD, 1997 Brown Univeristy
- Internship: 1998 Children's Hospital - Philadelphia
- Residency: 2000 Children's Hospital - Philadelphia
- Fellowship: 2003 Boston Children's Hospital
Committees, Societies, Councils
National Societies (and leadership roles):
American Academy of Allergy, Asthma and Immunology
Clinical Immunology Society
American College of Allergy Asthma and Immunology
American Association of Immunologists (Member)
American Academy of Pediatrics (Fellow)
Society for Natural Immunity (Member)
Society for Pediatric Research (Elected Member)
Pan-American Group for Immunodeficiencies (Member)
Robert A. Good Immunological Society (Elected Member)
American Society for Clinical Investigation (Elected Member)
Henry Kunkel Society (Elected Member)
American Society for Cell Biology (Member)
ASCB Ambassador for Baylor College of Medicine 2017
American Pediatric Society (Elected Member)
American Academy of Pediatrics Section on Allergy and Immunology- Executive Council Member 2016-2019
Board Certifications
- Allergy and Immunology
- Pediatrics
Honors & Awards
Research
Grants
Selected Publications
1. Vargas-Hernandez, A, Mace, EM, Zimmerman, O, Zerbe, CS, Freeman, AF, Rosenzweig, S, Leiding, JW, Torgerson, T, Altman, MC, Schussler, E, Cunningham-Rundles, C., Chinn, IK, Hanson, IC< Rider, NL, Holland, SM, Orange, JS, Forbes, LR. Ruxolitinib partially reverses functional NK cell deficiency in patients with STAT1 gain-of-function mutations 2017 J. Allergy Clin. Immunol. PMID: 2911217
2. Mamonkin, M, Mukherjee, M, Srinivasan, M, Sharma, S, Gomes-Silva, D, Mo, F, Krenciute, G, Orange, JS, Brenner, MK. Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T cell malignancies. 2017 Cancer Immunol. Res. PMID: 29076555
3. Nishimura, CD, Brenner, DA, Mukherjee, M, Hirsch, RA, Ott, L, Wu, MF, Liu, H, Dakhova, O, Orange, JS, Brenner, MK, Lin, CY, Arber, C. C-MPL provides tumor-targeted T cell receptor transgenic T cells with co-stimulation and cytokine signals. 2017 Blood PMID: 29054706
4.Gomes-Silva, D, Mukherjee, M, Srinivasan, M, Krenciute, G, Dakhova, O, Zheng, Y, Cabral, JMS, Rooney, CM, Orange, JS, Brenner, MK, Mamonkin, M. Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent. 2017 Cell Rep. 21:17-26 PMID: 28978471
5. Bielamowicz, K, Fousek, K, Byrd, TT, Samaha, H, Mukherjee, M, Aware, N, Wu M-F, Orange, JS, Sumazin, P, Man, T-K, Joseph, SK, Hedge, M, Ahmed, N. Trivalent CAR T-cells overcome interpatient antigenic variability in glioblastoma. 2017 Neuro-Oncology PMID: 29016929
For a complete list of publications, please visit PubMed.gov